• The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
  • Subscribe
  • Sign in
  • Pharma
  • Medtech
  • Biotech
  • Science
  • Events
  • Careers
  • Jobs
  • Opinion & Debate
  • The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
Menu
  • Subscribe
  • Sign in
Clinical Trials

Bavarian Nordic initiates Phase 2 trial

Malin Otmani

-

March 27, 2018

Share article on X
Share article on Linkedin


Published: March 27, 2018

Top stories

Column – November 22, 2026

What the previous government did well and what to expect now

After three decades in the industry, I can conclude that decision-makers have a growing understanding of the strategic importance of Swedish life science. After all, this is where highly skilled jobs are created and the image of Sweden as an innovative nation is fostered, not to mention the economic surplus generated by life science exports.

Global report – November 20, 2026

Pfizer licenses in vivo CAR-T programs

Pfizer has signed an exclusive licensing deal with China-based Starna Therapeutics for three in vivo CAR-T programs targeting autoimmune diseases. Starna receives USD 330 million upfront and could earn up to USD 2.3 billion more in development and commercial milestones, plus royalties on net sales.

Business article – November 19, 2026

Evaxion refocuses on cancer vaccines

Evaxion is shifting its strategy to concentrate on immuno-oncology. It will use its AI-Immunology platform to discover new cancer targets and develop cancer vaccines, and it will also make some changes to its organization.

Collaboration – November 19, 2026

Gates Foundationand NordForsk partner on women’s health

The Gates Foundation and NordForsk have signed a declaration to accelerate progress in women’s health by strengthening research, evidence, and innovation that can improve the lives of women and girls.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

Related posts

Clinical Trials - November 19, 2026

First patient dosed in Cereno’s PAH trial

Cereno Scientific has dosed the first patient in EPIMODE, its global Phase IIb trial of the lead drug candidate CS1 in pulmonary arterial hypertension (PAH). This first dose formally launches the trial, which will evaluate CS1’s efficacy, optimal dose, safety, and tolerability, as well as its potential as a disease-modifying treatment.

Clinical Trials - November 17, 2026

Oncoinvent’s Radspherin clears first randomized safety review

Oncoinvent’s alpha radiopharmaceutical Radspherin has shown no treatment-related serious adverse events in the first interim safety analysis of its ongoing randomized Phase 2 trial in ovarian cancer.

Clinical Trials - November 10, 2026

Survodutide passes Phase 3 heart safety test

Boehringer Ingelheim’s obesity drug survodutide, licensed from Zealand Pharma, did not increase the risk of major cardiovascular events compared with placebo in the Phase 3 SYNCHRONIZE-CVOT trial. With this result, the registrational SYNCHRONIZE program in obesity is complete.

Clinical Trials - November 9, 2026

Novo’s ziltivekimab fails to cut heart events in full ZEUS data

Full results from Novo’s Phase 3 ZEUS trial confirm that the IL-6 inhibitor ziltivekimab did not reduce the risk of heart attack, stroke or cardiovascular death in people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation. The data were presented at the American Heart Association’s Scientific Sessions 2026 and published in the New England Journal of Medicine.

Clinical Trials - November 6, 2026

Second Gubra-partnered obesity drug moves into Phase 2

Boehringer Ingelheim has started Phase 2 development of BI 3034701, a potential first-in-class GLP-1/GIP/NPY2 triple receptor agonist partnered with Gubra, triggering a EUR 10 million milestone payment, Gubra said in its third-quarter trading statement. It is the second Gubra-partnered obesity program to reach Phase 2 this year, after AbbVie’s ABBV-295.

Clinical Trials - November 5, 2026

New data supports Herantis’ Phase II design

Finnish Herantis Pharma has extended the placebo-controlled period of its upcoming Phase II study of HER-096 in Parkinson’s disease. The company points to newly published evidence that smartphone-based motor assessments detect disease progression more sensitively than conventional clinical measures.

Clinical Trials - November 4, 2026

Abera cleared for first-in-human trial

Uppsala-based Abera Bioscience has received approval from the Dutch Central Committee on Research Involving Human Subjects (CCMO) to start a Phase I trial of its nasal pneumococcal vaccine candidate Ab-01.12. The approval marks the company’s move from preclinical to clinical development.

Sign up to our newsletter: Nordic Life Science News!

I confirm that I want to subscribe to newsletters from Nordic Life Science and that Nordic Life Science has the right to save my email address. Read our privacy policy here

Read the latest issue!

Sign up for a subscription and read our latest digital issue today.

Sign up
Sign up

The leading life science news channel in the Nordic region.

© NLS Media Group AB – All rights reserved

Digital and print
  • The magazine
  • Subscribe
  • Newsletter
More information
  • About us
  • Contact
  • Advertising
Social media
  • LinkedIn
  • Bluesky
  • X
NLS Media Group AB

St Paulsgatan 13

118 46 Sweden

info@nlsnews.com

+46-8-588 941 51

  • Cookies
  • Data management and privacy policy

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.